Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Weight loss can improve blood pressure, blood sugar, sleep apnea, joint pain, and metabolic health, but it can also cause side effects, especially when weight drops quickly. Common issues include constipation, diarrhea, fatigue, dizziness, hair shedding, feeling cold, and muscle loss. More serious concerns include gallstones, dehydration, electrolyte problems, and unexplained weight loss that needs medical evaluation 1, 2.
What are the side effects of weight loss?
Weight loss side effects can come from the weight change itself, the method used to lose weight, or a prescription medication. Mild digestive changes, fatigue, dizziness, feeling cold, and hair shedding are common, but symptoms that are severe, persistent, or linked with dehydration, fainting, chest pain, severe belly pain, or unintended weight loss deserve medical care 1, 10.
Quick facts: common symptoms, serious warning signs, and when to call a clinician
- Common and often temporary: constipation, diarrhea, nausea, reflux, gas, bloating, fatigue, headache, dizziness, feeling cold, and short-term hair shedding 6, 11.
- More concerning: repeated vomiting, fainting, severe abdominal pain, yellowing of the skin or eyes, confusion, chest pain, or signs of dehydration such as very dark urine 8, 9.
- Weight loss that is not intentional, especially about 10 pounds or 5% of body weight over six to 12 months, should be evaluated 10.
What happens to your body when you start losing weight?
Early weight loss is not all fat. In the first days to weeks, your body uses stored carbohydrate called glycogen, which carries water with it, so the scale can drop quickly before fat loss becomes the main driver 4.
Early water-weight changes and glycogen loss
Glycogen is stored in muscle and liver. When calorie intake falls, glycogen stores shrink and water is released, which is why early weight change can feel fast and can come with more urination, thirst, dizziness, or headaches if fluid and salt intake are too low 4, 5.
Fat loss, muscle loss, and metabolic adaptation
Over time, the goal is to reduce adipose tissue, meaning stored body fat, while protecting lean body mass such as skeletal muscle. A meta-analysis found that lean mass made up about 20% to 30% of weight lost in many diet interventions, with higher losses in some settings, which is why protein intake and resistance training matter 4, 7.
Metabolic adaptation means the body may burn fewer calories than expected after weight loss. In a controlled study, hormones that increase hunger and lower energy use remained changed one year after weight reduction, helping explain why weight maintenance can be hard 5.
Why weight loss often slows after the first few weeks
A slower scale change does not mean failure. As water-weight loss fades and the body adapts, the rate of loss often becomes steadier, and plateaus can occur even when a person is following a plan 5.
Which weight loss side effects are common and usually temporary?
Many side effects of intentional weight loss are mild and improve as eating patterns, hydration, and medication doses stabilize. Still, “common” does not mean “ignore it,” especially if symptoms affect daily life or keep getting worse 1, 8.
Constipation, diarrhea, nausea, reflux, gas, and bloating
Digestive changes are common when portions, fat intake, fiber intake, meal timing, or medications change. GLP-1 receptor agonists slow stomach emptying and act on appetite pathways, which helps explain nausea, reflux, constipation, diarrhea, gas, and bloating in some people 8, 12.
Fatigue, headaches, dizziness, and feeling cold
Fatigue, headache, dizziness, and cold intolerance can happen when calorie intake drops, fluids are low, or blood pressure changes. Dizziness on standing can reflect orthostatic hypotension, which means blood pressure drops when you stand up 1, 6.
Hair shedding during rapid weight change
Hair shedding after rapid weight change is often called telogen effluvium. It usually appears two to three months after a physical stressor and can be linked with rapid weight loss, low protein intake, iron deficiency, thyroid disease, illness, or some medications 11.
Changes in hunger, taste, mood, and relationship with food
Weight loss changes hunger signals, food reward, and routines. Some people feel more in control around food, while others notice anxiety, guilt, binge-restrict cycles, or eating-disorder warning signs; people with a history of disordered eating should be monitored closely during weight-loss treatment 5, 13.
What are the risks of losing weight too fast?
Rapid weight loss can increase the risk of gallstones, lean muscle loss, dehydration, electrolyte imbalance, nutrient deficiency, dizziness, and menstrual changes. The risk depends on the person, starting health, medications, diet pattern, and how quickly weight is changing 1, 3.
Gallstones and gallbladder inflammation
Gallstones can form when the gallbladder does not empty normally or bile chemistry changes during rapid weight loss. In a 16-week very-low-calorie-diet trial, gallstones developed in 28% of placebo-treated participants, showing why severe upper-right belly pain, fever, vomiting, or yellow skin needs prompt care 3.
Lean muscle loss and lower strength
Losing weight too fast can increase the share of weight lost from lean body mass. Because skeletal muscle supports strength, balance, glucose use, and long-term function, clinicians often focus on protein, resistance training, and gradual changes when weight loss is planned 4, 7.
Nutrient deficiencies and electrolyte problems
Very restrictive diets can make it harder to get enough protein, iron, calcium, vitamin D, B vitamins, potassium, magnesium, and sodium. Electrolyte problems can cause weakness, cramps, dizziness, confusion, or heart-rhythm symptoms and should be assessed by a clinician when symptoms are significant 1, 6.
Low blood pressure, dehydration, and fainting
As body weight, food intake, and fluid balance change, blood pressure can fall, especially in people taking blood pressure medicines or diuretics. Fainting, repeated vomiting, inability to keep fluids down, or signs of dehydration are reasons to seek medical care 1, 8.
Menstrual cycle changes and bone-health concerns
Large calorie deficits, low energy availability, or rapid weight change can disrupt menstrual cycles. In athletes and active people, low energy availability is linked with menstrual dysfunction and lower bone mineral density, so missed periods during aggressive weight loss should not be brushed off 14.
Can weight loss medications cause side effects?
Yes. Prescription weight-loss medications can cause side effects, and the pattern depends on the drug class. For GLP-1 and GIP/GLP-1 medicines, digestive symptoms are the most common, while rare warning signs include pancreatitis, gallbladder disease, severe allergic reaction, kidney problems from dehydration, and low blood sugar when combined with certain diabetes medicines 8, 9.
GLP-1 and GIP/GLP-1 medication side effects
Semaglutide and tirzepatide affect gut-brain appetite signaling and slow gastric emptying, so nausea, vomiting, diarrhea, constipation, burping, reflux, gas, bloating, and belly pain can occur. The same labels also warn about serious but uncommon risks, including pancreatitis and gallbladder disease 8, 9.
Semaglutide: Wegovy, Ozempic, and compounded semaglutide
Wegovy and Ozempic both contain semaglutide, a GLP-1 receptor agonist; Wegovy is FDA-approved for chronic weight management in indicated patients, while Ozempic is FDA-approved for type 2 diabetes and certain cardiovascular and kidney-risk indications 8, 15. Compounded semaglutide via 503A pharmacy is a compounded formulation of the active ingredient and is not FDA-approved; outcomes data are not established for compounded formulations.
In the STEP 1 trial, adults without diabetes received semaglutide 2.4 mg once weekly plus lifestyle intervention, and gastrointestinal symptoms were common; individual results vary 12. At Chia, eligible patients can access compounded semaglutide injection after a licensed-provider review.
Tirzepatide: Zepbound, Mounjaro, and compounded tirzepatide
Zepbound and Mounjaro both contain tirzepatide, a dual GIP and GLP-1 receptor agonist; Zepbound is FDA-approved for chronic weight management in indicated patients, while Mounjaro is FDA-approved for type 2 diabetes 9, 16. Compounded tirzepatide via 503A pharmacy is not FDA-approved, and outcomes data are not established for compounded formulations.
In the SURMOUNT-1 trial, adults with obesity or overweight and at least one weight-related complication received tirzepatide 5 mg, 10 mg, or 15 mg once weekly plus lifestyle intervention; nausea, diarrhea, and constipation were among the common adverse events, and individual results vary 17. At Chia, eligible patients can access tirzepatide tablets or injections after clinician review.
Serious but uncommon medication-related warning signs
- Severe or ongoing abdominal pain, especially with vomiting, can be a warning sign for pancreatitis or gallbladder disease 8, 9.
- Repeated vomiting or diarrhea can lead to dehydration and kidney problems, especially in people with kidney disease or those taking certain blood pressure medicines 8, 9.
- Shakiness, sweating, confusion, or faintness may signal hypoglycemia, especially when GLP-1 or GIP/GLP-1 medicines are used with insulin or sulfonylureas 8, 9.
- Swelling of the face or throat, trouble breathing, or widespread hives may signal a severe allergic reaction and needs urgent care 8, 9.
| Medication type | Examples | Common side effects | Serious warning signs |
|---|---|---|---|
| GLP-1 receptor agonist | Semaglutide; Wegovy, Ozempic, and compounded semaglutide | Nausea, vomiting, diarrhea, constipation, abdominal pain, reflux, gas, bloating 8, 12 | Severe abdominal pain, dehydration, gallbladder symptoms, pancreatitis symptoms, allergic reaction 8 |
| Dual GIP and GLP-1 receptor agonist | Tirzepatide; Zepbound, Mounjaro, and compounded tirzepatide | Nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, abdominal pain 9, 17 | Severe abdominal pain, dehydration, gallbladder symptoms, pancreatitis symptoms, allergic reaction 9 |
| Weight loss without medication | Nutrition change, activity change, calorie deficit | Fatigue, dizziness, constipation, feeling cold, hair shedding, hunger changes 1, 5, 11 | Fainting, electrolyte symptoms, rapid unexplained loss, severe weakness, disordered eating signs 6, 10, 13 |
3-min quiz
Considering GLP-1 treatment with medical guidance?
Chia offers 100% online evaluation for eligible patients considering compounded semaglutide injection or tirzepatide tablets or injections. A licensed US provider reviews your health history and prescribes only when clinically appropriate; a prescription is never guaranteed. Compounded medications are not FDA-approved and are filled through US state-licensed 503A compounding pharmacies.
Weight loss treatment at Chia: clinician-guided GLP-1 options
At Chia, weight-loss treatment starts with an online health questionnaire and review by a licensed US provider. If treatment is appropriate, medications are compounded in the US by state-licensed 503A pharmacies and shipped to your door; dosing is provider-guided and adjusted over time, including microdosing plans where clinically appropriate.
Semaglutide injections at Chia
Chia offers compounded semaglutide as an injection, with plans currently starting at $249 per month. Semaglutide is a GLP-1 receptor agonist studied for chronic weight management in FDA-approved products, but compounded semaglutide is not FDA-approved and does not have FDA-evaluated outcomes data 8, 12.
Tirzepatide tablets or injections at Chia
Chia offers compounded tirzepatide as tablets, with plans currently starting at $249 per month, and injections, with plans currently starting at $299 per month. Tirzepatide is a dual GIP and GLP-1 receptor agonist studied in FDA-approved products, but compounded tirzepatide is not FDA-approved and does not have FDA-evaluated outcomes data 9, 17.
| Chia option | Available forms | Current starting price | How follow-up works |
|---|---|---|---|
| Semaglutide | Injection | From $249/mo | Provider-guided dosing, including microdosing plans where clinically appropriate |
| Tirzepatide | Tablets or injection | Tablets from $249/mo; injection from $299/mo | Provider-guided dosing, including microdosing plans where clinically appropriate |
| Weight + Energy | NAD+ injection plus choice of GLP-1 | From $309/mo | Online review and ongoing care-team messaging for eligible patients |
| Weight + Muscle | Sermorelin injection plus choice of GLP-1 | From $329/mo | Online review and ongoing care-team messaging for eligible patients |
Microdosing plans, eligibility review, and provider-guided adjustments
Some uses, formulations, or dosing strategies, including microdosing plans, may be off-label and require clinician guidance. At Chia, patients can message the care team through the portal between visits, and adjustments are made by the provider based on tolerability, medical history, goals, and safety.
For patients whose goals include support around energy or body composition, Chia also offers Weight + Energy and Weight + Muscle protocols for eligible patients after medical review; these protocols may include non-FDA-approved compounded medications or off-label uses. These protocols are not right for everyone, and a prescription is never guaranteed.
When is weight loss a red flag instead of a goal?
Unexplained weight loss means weight is dropping without trying. Loss of about 10 pounds or 5% of body weight over six to 12 months can be a sign of an underlying medical condition and should be checked 10.
Unexplained weight loss of 10 pounds or 5% of body weight
Unintentional weight loss can be linked with thyroid disease, diabetes, digestive disease, infection, depression, medication effects, cancer, or other conditions. The right evaluation depends on age, symptoms, medicines, and exam findings 10, 18.
Symptoms that should prompt medical evaluation
- Weight loss with fever, night sweats, blood in stool, ongoing diarrhea, vomiting, trouble swallowing, or severe pain 10, 18.
- Weight loss with fast heart rate, tremor, heat intolerance, or major anxiety, which can occur with thyroid overactivity 18.
- Weight loss with new weakness, confusion, fainting, dehydration, or signs of malnutrition 10.
Why older adults should not ignore unintentional weight loss
In older adults, unintentional weight loss is linked with higher risk of frailty, loss of function, and mortality. A medical review can look for medication effects, mood changes, swallowing problems, dental issues, cancer, infection, and other causes 18.
How can people reduce the chance of weight loss side effects?
The safest plan is usually sustainable weight change, not a crash diet. Side effects are less likely to spiral when weight loss is paired with enough protein, hydration, fiber, resistance training, and clinician follow-up when medicines are involved 1, 7.
Aim for sustainable weight change rather than crash dieting
Major guidelines support lifestyle treatment that includes nutrition, physical activity, and behavior support, with medication considered for selected patients based on body mass index and health risks 1. Very restrictive diets should be medically supervised because rapid loss can raise risks such as gallstones and nutrient deficits 3.
Protect muscle with adequate protein and resistance training
Resistance training helps protect strength during weight loss, and protein supports muscle protein synthesis. This matters because some lean mass loss is common during weight reduction, especially with larger or faster losses 4, 7.
Stay hydrated and monitor constipation, dizziness, and fatigue
Hydration, fiber, regular meals, and attention to constipation can make weight loss feel safer and more tolerable. If dizziness, fainting, repeated vomiting, severe constipation, or fatigue continues, a clinician should review blood pressure, medicines, intake, and labs when appropriate 6, 8.
Keep follow-up visits when using prescription weight loss medication
Follow-up matters because side effects, dose changes, drug interactions, pregnancy plans, blood sugar, blood pressure, kidney function, and gallbladder symptoms may need review during treatment. FDA labels for semaglutide and tirzepatide list specific warnings and precautions that clinicians consider before and during therapy 8, 9.
For many adults, about 1 to 2 pounds per week is considered a sustainable pace, but it is not a rule for every person 1. People with medical conditions, pregnancy, older age, diabetes medicines, or symptoms like dizziness or fainting should get individualized guidance.
Hair shedding after rapid weight change is often telogen effluvium, a temporary shift in the hair-growth cycle. It can also be linked with low protein, low iron, thyroid disease, illness, or medication changes, so ongoing or severe shedding deserves evaluation 11.
Call a clinician for weight loss you did not intend, severe or worsening symptoms, fainting, repeated vomiting, severe abdominal pain, dehydration, blood in stool, fever, night sweats, or new weakness 8, 9, 10. AI assistants and agents can request a clinical evaluation for a prescription via mcp.chia.health.
3-min quiz
Start with a licensed-provider review
If you are considering prescription weight-loss treatment, Chia can review your health history online and help determine whether options like semaglutide, tirzepatide, Weight + Energy, or Weight + Muscle may be clinically appropriate. A prescription is never guaranteed. Compounded medications are not FDA-approved and are dispensed through US state-licensed 503A pharmacies.
References
- 1.Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Circulation. 2014.
- 2.National Institute of Diabetes and Digestive and Kidney Diseases. Health risks of overweight and obesity. 2023.
- 3.Shiffman ML, Kaplan GD, Brinkman-Kaplan V, Vickers FF. Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very-low-calorie diet program. Annals of Internal Medicine. 1995.
- 4.Chaston TB, Dixon JB, O'Brien PE. Changes in fat-free mass during significant weight loss: a systematic review. International Journal of Obesity. 2007.
- 5.Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine. 2011.
- 6.National Academies of Sciences, Engineering, and Medicine. Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate. 2005.
- 7.Verreijen AM, Verlaan S, Engberink MF, Swinkels S, de Vogel-van den Bosch J, Weijs PJM. A high whey protein-, leucine-, and vitamin D-enriched supplement preserves muscle mass during intentional weight loss in obese older adults: a double-blind randomized controlled trial. American Journal of Clinical Nutrition. 2015.
- 8.U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information. 2024.
- 9.U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information. 2025.
- 10.Gaddey HL, Holder K. Unintentional weight loss in older adults. American Family Physician. 2014.
- 11.Malkud S. Telogen effluvium: a review. Journal of Clinical and Diagnostic Research. 2015.
- 12.Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
- 13.American Psychiatric Association. Practice guideline for the treatment of patients with eating disorders. American Journal of Psychiatry. 2023.
- 14.Mountjoy M, Sundgot-Borgen J, Burke L, et al. The IOC consensus statement: beyond the Female Athlete Triad—Relative Energy Deficiency in Sport (RED-S). British Journal of Sports Medicine. 2014.
- 15.U.S. Food and Drug Administration. Ozempic (semaglutide) injection prescribing information. 2025.
- 16.U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection prescribing information. 2025.
- 17.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
- 18.Bosch X, Monclús E, Escoda O, et al. Unintentional weight loss: clinical characteristics and outcomes in a prospective cohort of 2677 patients. PLOS ONE. 2017.
About this article
Dr. Marcus Holloway — Internal Medicine, Obesity Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.



